key: cord-0951472-3wmg7ex8 authors: Nguyen, Linh Chi; Bakerlee, Christopher W; McKelvey, T Greg; Rose, Sophie M; Norman, Alexander J; Joseph, Nicholas; Manheim, David; McLaren, Michael R; Jiang, Steven; Barnes, Conor F; Kinniment, Megan; Foster, Derek; Darton, Thomas C; Morrison, Josh title: Evaluating use cases for human challenge trials in accelerating SARS-CoV-2 vaccine development date: 2020-07-06 journal: Clin Infect Dis DOI: 10.1093/cid/ciaa935 sha: ee682a3b334a5f95b77cf0fca3145d8dcaf1de58 doc_id: 951472 cord_uid: 3wmg7ex8 Human challenge trials (HCTs) have been proposed as a means to accelerate SARS-CoV-2 vaccine development. We identify and discuss three potential use cases of HCTs in the current pandemic: evaluating efficacy, converging on correlates of protection, and improving understanding of pathogenesis and the human immune response. We outline the limitations of HCTs and find that HCTs are likely to be most useful for vaccine candidates currently in preclinical stages of development. We conclude that, while currently limited in their application, there are scenarios in which HCTs would be extremely beneficial. Therefore, the option of conducting HCTs to accelerate SARS-CoV-2 vaccine development should be preserved. As HCTs require many months of preparation, we recommend an immediate effort to (1) establish guidelines for HCTs for COVID-19; (2) take the first steps toward HCTs, including preparing challenge virus and making preliminary logistical arrangements; and (3) commit to periodically re-evaluating the utility of HCTs. As of June 12, 2020, SARS-CoV-2 has led to almost 7.5 million confirmed infections worldwide and over 400,000 deaths. 1 Organizations such as the Coalition for Epidemic Preparedness Innovations have advocated measures to shorten development times for vaccines against the virus, including conducting phase 1 clinical trials in parallel with animal testing. 2 Still, in February the World Health Organization (WHO) optimistically projected 12-18 months until a vaccine could be available, with potential further manufacturing and regulatory delays. 3 Human challenge trials (HCTs) present an opportunity to hasten SARS-CoV-2 vaccine development. In HCTs, volunteers are administered a vaccine candidate, followed by an infectious dose of pathogen. The outcomes of this infection are tracked, providing a unique opportunity to assess a vaccine candidate's performance. Historically, HCTs have provided crucial information about humanpathogen interactions. 4 HCTs have demonstrated the efficacy of cholera vaccines prior to large field trials and gave early indications regarding the possible efficacy of RTS,S/AS01, the leading malaria vaccine candidate. 5, 6 Eyal et al. suggested that HCTs could speed up SARS-CoV-2 vaccine development by several months and avert many deaths. 7 This and similar proposals have sparked substantial dialogue around HCTs. 8 In this paper, we discuss three potential use cases for HCTs in the current COVID-19 pandemic, the preparatory steps needed to make them possible, and how to proceed while deciding whether to conduct them. A c c e p t e d M a n u s c r i p t In the context of the COVID-19 pandemic, HCTs could help evaluate vaccine efficacy, identify correlates of protection, and understand pathogenesis and the immune response. HCTs could be used alongside an expanded safety trial to replace phase 3 trials, or in parallel with phase 3 trials to give an early indicator of efficacy. Eyal et al. proposed that HCTs could be used to test for efficacy and, in combination with a largescale short-term expanded phase 2 safety study, replace comparably lengthy phase 3 trials. 7 Phase 3 trials often take years and usually at least many months. 9 However, governments, vaccine manufacturers, and other stakeholders are currently moving to develop a vaccine at unprecedented speed. 10 The WHO Solidarity Trial expects to shorten the time to generate efficacy data from their trial to three to six months, if the trial is conducted in regions with high COVID-19 incidence or in high-risk populations such as healthcare workers. 11 Other stakeholders will likely conduct phase 3 trials with similar populations. 12 However, it might become harder to identify suitable populations at high risk of infection if COVID-19 incidence falls or fluctuates unpredictably due to social restrictions. 13 Two studies in China examining the effects of the potential drug treatment remdesivir were forced to shut down when unable to recruit enough patients due to low disease incidence. 14 With the necessary preparations and approvals in place, an HCT could take as little as two months to conduct and would require far fewer participants than a phase 3 trial due to viral exposure being guaranteed by the challenge. Therefore, HCTs could accelerate the licensure of a vaccine. Our two month estimate includes: There is precedent for licensing on the basis of HCT efficacy data: such data, in combination with conventional trials measuring safety and immunogenicity, provided the basis for licensing the first FDA-approved cholera vaccine. 15 However, HCTs replacing phase 3 trials would have to be accompanied by expanded safety trials, which would take additional time and might still not suffice for vaccine licensure. At a minimum, post-licensure trials would be necessary to continuously evaluate the vaccine's efficacy and safety. While collecting safety data, a vaccine that shows efficacy in HCTs may be approved for emergency use in high risk groups. Alternatively, HCTs could be used in conjunction with phase 3 trials to provide an early glimpse of efficacy in advance of phase 3 results. This could allow manufacturers to reallocate resources from less to more promising candidates. 16 A c c e p t e d M a n u s c r i p t Correlates of protection (CoPs) are biomarkers that correlate with protection against specific infection outcomes. HCTs could be used to identify or verify CoPs against disease endpoints.These CoPs could then be used as surrogate endpoints in phase 3 trials (instead of clinical endpoints), possibly expediting licensure 17 Vaccines that have been approved based on CoPs include vaccines against hepatitis B, H5N1 influenza, and Japanese encephalitis. 18, 19, 20 CoPs are typically identified in animal challenge models, observational studies, or early clinical phases. Some SARS-CoV-2 vaccine manufacturers have signaled their intention to look for secondary endpoints that might be important CoPs. 21 However, finding CoPs is a difficult task. Some viruses, such as rotavirus, have no firmly established CoPs despite years of searching. 22 If other trial designs fail, the controlled clinical setting of HCTs could provide greater opportunity to reveal causal links between secondary endpoints and protection. This could accelerate the progress of many different candidate vaccines. However, the prospect of finding CoPs is always uncertain. CoPs found in HCTs would likely have to be confirmed by data from natural infection, as was done with previous influenza CoPs, and vaccine candidates licensed based on CoPs should be assessed for efficacy post-licensure. 23 Notably, CoPs could only accelerate the generation of efficacy data and not safety data. severity, the disease's progression from infection, or the immune response upon re-infection. 26 Thereby, they could provide insights that would form a bedrock for medical countermeasure development efforts more broadly. HCTs may also help detect vaccine-enhanced disease. For example, animal models showed increased lung pathology after vaccination with whole SARS-CoV spike protein. 27 Notably, the evidence for vaccine-enhanced disease in SARS-CoV is limited to in vitro and animal models, with vaccination appearing protective overall. In humans, the clinical evidence for vaccine-enhanced disease in SARS-CoV is scant, and the evidence for SARS-CoV-2 even more so. As Eyal et al. propose, HCTs could be designed to minimize participants' exposure to vaccine-enhanced disease, with challenges occurring sequentially over small groups with incrementally increasing numbers of participants. 7 A c c e p t e d M a n u s c r i p t However, in contrast to a conventional clinical trial, HCTs may be unable to detect adverse events that are rare or have delayed onset. For example, time-lagged enhanced disease responses occurred in consecutive infections with different dengue serotypes. 28 This may simply be due to delayed exposure, but it is also possible that these effects only appear if sufficient time has passed between vaccination and infection. All these approaches are limited by the extent to which data gathered from HCTs can be generalized to the field. Historically, certain human challenge models have produced results that are generally predictive of performance in the field, 29 while others have not. 30 The generalizability of HCT results depends on several factors. From the perspective of participant risk, it is desirable to choose the minimum infectious dose of challenge virus required to induce mild disease in most participants, possibly using an attenuated challenge virus strain to achieve this result. However, it is possible that vaccine candidates will more effectively abrogate severe disease than mild illness, as has been seen with influenza vaccine candidates. 31 If such candidates were tested in HCTs with mild disease as its primary endpoint, their efficacy against severe disease may go undetected, along with associated CoPs. Additionally, if attenuated or otherwise engineered virus strains were used, they might generally offer less applicable results. If using wild-type virus strains or using severe disease as an HCT endpoint, whether effective therapeutic options are available at the time of conducting HCTs would become an even more important consideration for participant safety. Fourth, it may be difficult to generalize from results in pre-screened healthy young people to the broader global population. Responses to infection and vaccination can depend on age, immune status, comorbidities, genotype, and other factors. 32 That said, traditional phase 3 studies are not perfect in this regard either. They often exclude subsets of the population such as children and pregnant women. 33 A c c e p t e d M a n u s c r i p t HCTs' practical utility depends critically on how quickly they could be prepared and conducted. Some initial preparatory steps include: -convening experts and stakeholders to develop HCT protocols; -coordinating with vaccine manufacturers to design multi-arm trials; -gaining approval from institutional review boards and regulatory bodies; -establishing partnerships with clinical researchers and institutional sponsors; -securing access to ventilators, any available therapeutics, and other equipment to provide the highest standard of care to participants in case of severe disease. For the sake of speed, these steps could be partially parallelized. Beyond these, the three main timeconsuming steps-apart from vaccine production and initial clinical trials-are manufacturing challenge virus, conducting dose-finding studies, and potentially preparing clinical biocontainment units. Before HCTs are possible, a challenge virus must be produced under good manufacturing practice (GMP), which only a handful of manufacturers in the US and UK are equipped to do. Manufacturing involves contracting a production facility, securing raw materials, establishing a standardized protocol for production of high-quality material free of adventitious agents, producing and storing the virus stock, and conducting release testing. Experts disagree on how long this process would take. One estimate is that, when there are no supply chain problems, the first steps from contracting to establishing a protocol would likely take one to two months, production and storage at least several weeks, and release testing at least three to four months, although many experts expressed A c c e p t e d M a n u s c r i p t more optimistic timelines (B. L. Innis, personal communication, May 9, 2020). Finally, the virus must be FDA-approved prior to dose-finding studies. This timeline could be shortened if GMP-grade virus was already in production for other uses, e.g. for a live attenuated vaccine. Otherwise, starting production for HCTs could hasten other manufacturing timelines later on. Before HCTs can be performed, the infectious dose to be administered in challenges must be determined, typically via an escalation study. In escalation studies a small number of seronegative participants are initially administered a very low dose of virus. Participants would be followed for several weeks in a biocontainment unit to assess the presence and severity of any resultant infections. This process would be repeated with incrementally higher doses until some proportion of participants have reached the desired clinical endpoint. This means dose-finding studies carry appreciable risks for volunteers that must be weighed carefully. Experts estimated that a dosefinding study for a COVID-19 challenge model would take two to six months. Regulatory requirements for infectious dose-finding studies vary. 34 We estimate that, at maximum speed, manufacturing, validation and FDA approval of the challenge virus would take four months, and dose-finding four months, for a total of eight months. Given these timelines, it is unlikely that HCTs will support testing of the vaccine candidates currently in clinical trials. However, if these vaccines fail, HCTs could help accelerate the development of alternative vaccine candidates in earlier developmental stages, if approached with due urgency. The path to HCTs will involve dozens of players, and active coordination will be necessary to minimize lags arising from interdependencies among them. HCTs come with appreciable risks to study participants, research staff, and wider society. It will be important for volunteers, manufacturers, regulators, and other stakeholders to assess whether those outweigh the potential benefit. The risk to participants has been discussed extensively elsewhere. 35 It should be minimized by selecting volunteers with low risk of severe disease outcomes, providing state-of-the-art medical A c c e p t e d M a n u s c r i p t care, carefully selecting the virus strain and mode of administration, and assessing the need for a placebo group in HCTs testing vaccine candidates. 36 HCTs must implement an informed consent process that ensures participants understand they will be intentionally exposed to an infectious pathogen, and that this could cause them to get ill and suffer disease symptoms, including uncertain long-term effects and even death. 37 Participants must understand that, once exposed to the virus, they will only be allowed to leave the study facility when they no longer pose a risk to others, even if they decide to withdraw from the data collection aspect of the trial. Further, bioethicists and researchers should carefully weigh the virtues of compensation (e.g., paying respect to volunteers, enabling their participation) against its potential undesirable effects (e.g., undue inducement). 38 HCTs may also involve potential risks that are less direct. HCTs could unintentionally expose trial personnel to the virus, or accidentally release virus into the surrounding area, both of which could lead to wider outbreaks. Teams leading HCTs should consult the local community and other relevant stakeholders well beforehand and take all necessary measures to minimize these risks. 38 Finally, in rushing to conduct HCTs to evaluate SARS-CoV-2 vaccine candidates, the biomedical community may risk deleterious outcomes that could set back the field of human challenge research significantly. Recent research using human challenges has yielded valuable insights for the control of influenza, typhoid and other infectious diseases, and an overly hasty or mismanaged COVID-19 HCT could risk the gains from future HCTs. 39, 40 A c c e p t e d M a n u s c r i p t We presented three potential use cases for HCTs in accelerating SARS-CoV-2 vaccine development: evaluating efficacy, converging on CoPs, and improving understanding of pathogenesis and the human immune response. In each of these, HCTs offer distinct advantages due to the speed and richness of the data they could generate. However, practical and ethical considerations constrain the range of scenarios in which HCTs could actually influence vaccine development timelines. For example, even if HCTs were pursued immediately, it is unlikely they could provide efficacy data on the current phase 1 vaccine candidates soon enough to be useful. Nevertheless, there are still many scenarios in which the benefits generated by HCTs would likely outweigh their risks. For example, it is quite possible that we will reach the end of 2020 without any of the vaccine candidates currently in clinical trials having shown efficacy, but with one or more drugs having proven effective against severe COVID-19, and a range of vaccine candidates in early developmental stages. In such circumstances, it could make sense to run an ambitious, multi-arm HCT of, say, a dozen vaccine candidates in parallel with a multi-arm phase 3 trial. This could provide both rapid efficacy data to be used in down-selecting candidates and rapid confirmation of any CoPs indicated in phase 2 trials. A c c e p t e d M a n u s c r i p t To preserve the option to implement HCTs in such scenarios, we recommend an immediate, coordinated effort by all stakeholders to make the necessary preparations. These include: 1. convening experts to discuss the ethical and practical considerations associated with HCTs for COVID-19, concluding in a set of recommendations and guidelines for their use in the present pandemic and their role in the licensure process. The WHO and the NIH have already started this process. (Notably, this could provide useful guidance in the event of future pandemics as well.) 2. taking the first practical steps toward HCTs, including preparing challenge virus and making preliminary arrangements with volunteers, vaccine developers, regulators, academic institutions, and clinical researchers to run HCTs in situations where they are expected to be highly useful; 3. periodically conducting a systematic re-evaluation, and adjusting course based on the progress of the pandemic and the first drug and vaccine trials. HCTs have the potential to considerably shorten the COVID-19 pandemic, saving many lives and enabling economies and societies to return to normality. But we must act now to ensure this opportunity is not missed. A c c e p t e d M a n u s c r i p t World Health Organization. Coronavirus disease (COVID-19) pandemic. World Health Organization Developing COVID-19 vaccines at pandemic speed Coronavirus disease (COVID-19) press conference. World Health Organization Design, recruitment, and microbiological considerations in human challenge studies The utility of human challenge studies in vaccine development: lessons learned from cholera The development of the RTS,S malaria vaccine candidate: challenges and lessons Human challenge studies to accelerate coronavirus vaccine licensure Speed coronavirus vaccine testing by deliberately infecting volunteers? Not so fast, some scientists warn Vaccine R&D success rates and development times How clinical vaccine trials are speeding up in a pandemic Update on WHO Solidarity Trial -accelerating a safe and effective COVID-19 vaccine Choices in vaccine trial design in epidemics of emerging infections Tensions between research and public health: modelling the risks and benefits of SARS-CoV-2 vaccine field trials versus human infection challenge studies Gilead shares slip as a 2nd remdesivir COVID-19 trial halted in China Accessed 17 Vaxchora: the first FDA-approved cholera vaccination in the United States If a coronavirus vaccine arrives, can the world make enough? Nature Endpoints in vaccine trials Highlights of prescribing information. Audenz (influenza A (H5N1) monovalent vaccine, adjuvanted) Highlights of prescribing information. Ixiaro O (Japanese encephalitis vaccine, inactivated, adsorbed) Safety, tolerability and immunogenicity of INO-4800 for COVID-19 in healthy volunteers. ClinicalTrials.gov Correlates of protection for rotavirus vaccines: possible alternative trial endpoints, opportunities, and challenges Next-generation influenza vaccines: opportunities and challenges The effective rate of influenza reassortment is limited during human infection The time course of the immune response to experimental coronavirus infection of man A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge Accessed 26 Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year Phase 3 efficacy analysis of a typhoid conjugate vaccine trial in Nepal Asexual blood-stage malaria vaccine development: facing the challenges Convening on the influenza human viral challenge model for universal influenza vaccines, part 2: methodologic considerations Biological challenges to effective vaccines in the developing world BCG vaccination to protect healthcare workers against COVID-19 (BRACE) World Health Organization. Key criteria for the ethical acceptability of COVID-19 human challenge studies This one's important: Designing clinical trials for coronavirus treatments and vaccines. Statistical Modeling, Causal Inference, and Social Science The ethical challenge of infection-inducing challenge experiments Ethical goals of community consultation in research Influenza A reinfection in sequential human challenge: implications for protective immunity and "universal" vaccine development Generating the evidence for typhoid vaccine introduction: considerations for global disease burden estimates and vaccine testing through human challenge A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t